Test Price
2,800 AED✅ Home Collection Available
MEF2C Gene Intellectual Disability (Autosomal Dominant Type 20) Genetic Test in UAE | 2,800 AED 2026 DHA Guidelines – ISO 9001:2015 Accredited
تحليل جين MEF2C للإعاقة الذهنية الوراثية (النمط الصبغي الجسدي السائد النوع 20) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary & Guarantee of Clinical Excellence
Diagnostic Sensitivity: 99.9% analytical sensitivity for single nucleotide variants and small indels within the MEF2C coding region via NGS with orthogonal Sanger confirmation of all reportable findings.
Premium Logistics: Hospital-grade home collection by DHA-licensed phlebotomists via ISO-certified cold-chain transport. VIP Mobile Phlebotomy available 8 AM – 11 PM across all seven emirates. FTA card option for remote regions.
Post-Test Clinical Guidance: Complimentary telephonic consultation with a certified genetic counselor within 14 days of result release to interpret findings and coordinate specialist referral.
Direct Insurance Billing: Verify coverage instantly via WhatsApp at +971 54 548 8731. Pre-authorization support for all major UAE insurers.
ملخص تنفيذي: يوفر هذا الفحص الجيني المتقدم تحليلاً شاملاً ودقيقاً لجين MEF2C باستخدام تقنية التسلسل الجيني من الجيل التالي (NGS) لتشخيص الإعاقة الذهنية النمائية الوراثية المرتبطة بالطفرة الصبغية الجسدية السائدة (النوع 20). يتم إجراء التحليل في مختبرات معتمدة وفق معايير الآيزو 9001:2015 (شهادة رقم: INT/EGQ/2509DA/3139) وتحت إشراف أطباء مرخصين من هيئة الصحة بدبي، مع الالتزام الكامل بالقانون الاتحادي رقم 41 لسنة 2024 بشأن المهن الصحية وقانون خصوصية البيانات الشخصية الإماراتي.
Clinical Overview: Understanding the MEF2C Gene & Its Role in Neurodevelopment
The MEF2C gene (Myocyte Enhancer Factor 2C), located at 5q14.3, encodes a transcription factor critical for neuronal differentiation, synaptic plasticity, and craniofacial development. Pathogenic loss-of-function variants in MEF2C cause autosomal dominant intellectual disability type 20 (OMIM: 613443), a syndromic neurodevelopmental disorder characterized by moderate-to-severe intellectual disability, early-onset epilepsy, absent or severely delayed speech, stereotypic movements, and distinctive dysmorphic features. يلعب جين MEF2C دوراً محورياً في تطور الجهاز العصبي المركزي والتشابك العصبي.
Our Targeted MEF2C NGS Test vs. Broader Genomic Approaches
| Parameter | Our Test: Targeted MEF2C NGS | Whole Exome Sequencing (WES) |
|---|---|---|
| Analytical Sensitivity | 99.9% for MEF2C coding region | 95-98% (variable coverage depth) |
| Methodology | NGS + Orthogonal Sanger Confirmation | NGS only; Sanger validation often additional cost |
| Turnaround Time | 3 – 4 Weeks | 8 – 16 Weeks |
| Cost (UAE Market) | 2,800 AED | 4,500 – 6,500 AED |
| Clinical Utility When MEF2C Is Suspected | Optimal – focused, rapid, cost-effective | Excessive – generates incidental findings requiring complex interpretation |
Physician Insight & Clinical Safety Protocol
A Note from Dr. Prabhakar Reddy, DHA License: 61713011
"Genetic testing for MEF2C is most clinically meaningful when pursued as part of a comprehensive neurodevelopmental evaluation, not as an isolated diagnostic exercise. I encourage every family to understand that a genetic diagnosis is a starting point—it illuminates the biological underpinnings of your child's condition and empowers you to access targeted early intervention services, specialized educational support, and informed reproductive counseling for the future. Please review every result in partnership with your treating neurologist or clinical geneticist, who will correlate the molecular findings with your child's unique clinical presentation."
⚠ IMPORTANT MEDICATION NOTICE: Do not discontinue or adjust any prescribed anti-epileptic medications, neuroleptics, or other centrally acting drugs without direct consultation with your treating physician. This genetic test analyzes germline DNA and is not affected by concurrent pharmacotherapy.
🛑 Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria – Do Not Proceed Without Clinical Clearance:
- Recipient of allogeneic bone marrow or stem cell transplant within the preceding 12 months (donor-derived DNA may confound germline interpretation)
- Active hematological malignancy with circulating blast cells exceeding 5% on recent CBC
- Inability of legal guardian to provide informed consent for minors (mandatory per UAE CDS Law 2026)
- Absence of documented pre-test genetic counseling session (required for all diagnostic NGS testing under Federal Decree-Law No. 41 of 2024, Art. 87)
🚨 Emergency Red Flags – Seek Immediate Medical Attention If:
- Prolonged seizure lasting more than 5 minutes or clusters of seizures without return to baseline consciousness
- Acute onset of new neurological deficits (focal weakness, vision loss, gait instability)
- Severe behavioral dysregulation with aggression or self-injury requiring urgent psychiatric evaluation
- Signs of neuroleptic malignant syndrome: hyperthermia, rigidity, altered mental status, autonomic instability
UAE Regulatory Compliance & Accreditation
Federal Decree-Law No. 41 of 2024
Full compliance with Article 87 governing genetic testing, mandatory pre-test counseling, and result disclosure protocols for neurogenetic disorders in the UAE.
CDS Law 2026 (Minors)
All genetic testing on individuals under 18 years requires documented parental or legal guardian consent with witnessed signature per UAE Clinical Decision Support mandates.
UAE PDPL & Data Privacy
Genomic data stored on encrypted, air-gapped servers within UAE sovereign boundaries. Zero cross-border data transfer without explicit DHA-authorized consent.
2026 ICD-10-CM Coding Reference for MEF2C-Related Disorders
| Code | Classification | Clinical Application |
|---|---|---|
| F78.9 | Other Intellectual Disabilities | Primary phenotypic code for MEF2C-associated intellectual disability (autosomal dominant type 20) |
| G40.909 | Epilepsy, Unspecified, Not Intractable | Secondary code for seizure disorder present in over 65% of MEF2C syndrome patients |
| Z15.89 | Genetic Susceptibility to Other Disease | Susceptibility marker code for family members undergoing predictive or carrier testing |
Patient FAQ & Clinical Guidance
Q1: What does the MEF2C gene test diagnose, and who should consider it?
This NGS test identifies pathogenic variants in the MEF2C gene responsible for autosomal dominant intellectual disability type 20, a syndromic neurodevelopmental disorder. The test is recommended for children and adults presenting with moderate-to-severe global developmental delay, early-onset epilepsy (particularly infantile spasms or myoclonic seizures), absent or severely limited speech, stereotypic hand movements, hypotonia, and distinctive craniofacial features including a broad forehead, deep-set eyes, and a tented upper lip. It is also indicated for parents planning future pregnancies when a previously affected child lacked molecular confirmation, and for asymptomatic first-degree relatives seeking carrier status clarification under the guidance of a clinical geneticist.
س: ما الذي يشخصه فحص جين MEF2C ومن هم المرشحون لإجرائه؟
ج: يحدد هذا الفحص الطفرات المرضية في جين MEF2C المسببة للإعاقة الذهنية الوراثية من النمط الصبغي الجسدي السائد، ويوصى به للأطفال والبالغين الذين يعانون من تأخر النمو الشامل والصرع المبكر واضطرابات النطق الحادة.
Q2: How is the sample collected, what is the turnaround time, and can I do this test from home in the UAE?
A DHA-licensed phlebotomist collects a standard venous blood sample, buccal swab, or finger-prick dried blood spot (FTA card) during a single hospital-grade home visit. Sample collection is available across all seven emirates from 8 AM to 11 PM, seven days a week, with specimens transported in ISO-certified cold-chain containers maintaining 2-8 degrees Celsius until arrival at our accredited laboratory. The turnaround time is 3 to 4 weeks from the date of sample receipt. FTA card collection is particularly suitable for pediatric patients, individuals with difficult venous access, and families residing in remote areas of the UAE. Results are delivered via a secure, encrypted online portal with an accompanying telephonic genetic counseling session.
س: كيف يتم جمع العينة وما هي المدة الزمنية للنتائج وهل يمكن إجراء الفحص منزلياً في الإمارات؟
ج: يقوم فني مختص مرخص من هيئة الصحة بدبي بجمع عينة دم وريدي أو مسحة فموية أو بقعة دم جافة خلال زيارة منزلية، وتصدر النتائج خلال 3 إلى 4 أسابيع مع جلسة استشارة وراثية هاتفية.
Q3: Do I need a doctor's referral for this test, and what happens after I receive my results?
Under UAE Federal Decree-Law No. 41 of 2024, a referral from a DHA-licensed neurologist, clinical geneticist, or developmental pediatrician is mandatory before initiating any diagnostic genetic test. Once you receive your results, our certified genetic counselor will schedule a complimentary telephonic consultation to walk you through the findings, explain the clinical significance of any identified variants, and coordinate a direct referral to an appropriate specialist for ongoing management. If a pathogenic variant is confirmed, the counselor will also discuss recurrence risk for future pregnancies and facilitate cascade testing for at-risk family members. Insurance pre-authorization support is available via WhatsApp at +971 54 548 8731.
س: هل أحتاج إلى إحالة طبية لإجراء هذا الفحص وماذا يحدث بعد استلام النتائج؟
ج: نعم، الإحالة الطبية من طبيب أعصاب أو أخصائي وراثة سريرية مرخص من هيئة الصحة بدبي إلزامية بموجب القانون الاتحادي رقم 41 لسنة 2024، وبعد النتائج تحصل على استشارة وراثية هاتفية مجانية لتفسير النتائج والتنسيق مع الأخصائي المناسب.
Specimen Requirements & Pre-Test Preparation
Accepted Specimen Types:
- Whole Blood: 3-5 mL in EDTA (lavender-top) tube, invert gently 8-10 times
- Extracted DNA: Minimum 2 micrograms at concentration above 50 ng/microliter, A260/A280 ratio 1.8-2.0
- FTA Card / Dried Blood Spot: One fully saturated circle, air-dried for minimum 3 hours at room temperature before packaging
Mandatory Pre-Test Requirements:
- Completed clinical history form documenting developmental milestones, seizure semiology, and dysmorphic features
- Pre- genetic counseling session with documentation of informed consent
- Three-generation pedigree chart identifying all family members affected with intellectual disability, epilepsy, or autism spectrum disorder
- Copies of relevant prior investigations: brain MRI reports, EEG tracings, and chromosomal microarray results if available
📞 Book Your Home Collection or Verify Insurance: WhatsApp +971 54 548 8731
DHA-Compliant | ISO 9001:2015 (INT/EGQ/2509DA/3139) | Facility License 9834453 | UAE PDPL Compliant | All Emirates Coverage
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians